Current adjuvant treatment modalities for gastric cancer: From history to the future

Table 2 Features of major adjuvant chemoradiotherapy trials for gastric cancer

Ref.	CT Regimen without RT/with RT	n (total)	D2 rates	G3-G4 toxicity (hem/GI)	Completeness of treatment	RT technique
Macdonald et al[6]	Bolus 5-FU + LV/bolus 5-FU + LV	556	10%	54%/33%	64%	2D
Lee et al[43]	FP/capecitabine	31	100%	50.2%/12.8%	74.20%	2D
Zhu et al[57]	Bolus 5-FU + LV/bolus 5-FU + LV	380	100%	5.9%/7.5%	NA	IMRT
Leong et al[44]	ECF/inf 5-FU	54	NA	66%/28%	NA	3D
Schwartz et al[49]	PC (PCF arm closed)/PC	78	NA	24%/33% (for PC arm)	NA	3D
Lee et al[4]	XP/capecitabine	458	100%	48.4%/19%	81.7%	3D

CT: Chemotherapy; RT: Radiotherapy; D2: D2 lymph node dissection; G3-G4: Grade 3-grade 4; hem: Hematologic; GI: Gastrointestinal; NA: Not available; 5-FU: 5-fluorouracil; LV: Leucovorin; inf: Infusional; FP: 5-FU, cisplatin; ECF: Epirubicin, cisplatin, 5-FU; PC: Paclitaxel, cisplatin; PCF: Paclitaxel, cisplatin, 5-FU; XP: Capecitabine, cisplatin; 2D: Two-dimensional; 3D: Three-dimensional; IMRT: Intensity modulated radiotherapy.